Table of Contents Author Guidelines Submit a Manuscript
International Journal of Pediatrics
Volume 2015, Article ID 349795, 7 pages
http://dx.doi.org/10.1155/2015/349795
Clinical Study

Two Oral Midazolam Preparations in Pediatric Dental Patients: A Prospective Randomised Clinical Trial

1Department of Pediatric Dentistry and Oro-Maxillofacial Developmental Disease Research Center, Faculty of Dentistry, Guilan University of Medical Sciences, Rasht 4194173774, Iran
2Guilan University of Medical Sciences, Rasht, Iran
3Department of Pediatric Psychiatry, Shafa Hospital, Guilan University of Medical Sciences, Rasht, Iran
4Department of Pediatric Anesthesiology, Mofid Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5Medical Research Development Center, Mofid Children’s Hospital, Shahid Beheshti University of Medical Sciences, Iran

Received 5 December 2014; Accepted 27 April 2015

Academic Editor: Naveed Hussain

Copyright © 2015 Katayoun Salem et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Pharmacological sedation is an alternative behavior management strategy in pediatric dentistry. The aim of this study was to compare the behavioral and physiologic effects of “commercially midazolam syrup” versus “orally administered IV midazolam dosage form (extemporaneous midazolam (EF))” in uncooperative pediatric dental patients. Eighty-eight children between 4 to 7 years of age received 0.2–0.5 mg/kg midazolam in this parallel trial. Physiologic parameters were recorded at baseline and every 15 minutes. Behavior assessment was conducted objectively by Houpt scale throughout the sedation and North Carolina at baseline and during injection and cavity preparation. No significant difference in behavior was noted by Houpt or North Carolina scale. Acceptable behavior (excellent, very good, and good) was observed in 90.9% of syrup and 79.5% of EF subjects, respectively. Physiological parameters remained in normal range without significant difference between groups and no adverse effect was observed. It is concluded that EF midazolam preparation can be used as an acceptable alternative to midazolam syrup.